SEC Tracker
Get the app

Harmony Biosciences Holdings HRMY

Harmony Biosciences CEO to retire in 2026

Form
8-K
Filed
Importance
Major
  1. Jeffrey M. Dayno to retire as CEO and director on Dec 31, 2026
  2. Peter Anastasiou appointed as new CEO effective Jan 1, 2027
  3. Company reaffirms 2026 WAKIX revenue guidance of $1.0B-$1.04B

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Harmony Biosciences Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Travere Therapeutics TVTX public float $1.3B, Jun 30, 2025
  2. Ani Pharmaceuticals ANIP public float $1.3B, Jun 30, 2025
  3. Celldex Therapeutics CLDX public float $1.3B, Jun 30, 2025
  4. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025
  5. Innoviva INVA public float $1.3B, Jun 30, 2025